Application of the novel framework has identified the dyslipidemia medication gemfibrozil as a candidate drug to reduce Alzheimer’s disease risk.
Translating Genomics to Therapeutics for Atrial Fibrillation
A multifront Cleveland Clinic research project aims to use $14 million in NIH funding to identify mechanisms and targets underlying AF that may lead to personalized therapies.
Evolutionary Games Have High Stakes in Treatment-Resistant Cancer
The development of treatment resistance in cancer is driven by the same evolutionary mechanisms that drive change and escape from therapy in most human diseases.
Survivorship is the Focus of New Cancer Genomics Program
New survivorship program helps patients transition from cancer treatment to recovery while addressing their future risks through next-generation sequencing.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
New Clinic Helps Cancer Patients Decipher Results of Genome Sequencing
New virtual genomics clinic provides custom-tailored cancer treatments by targeting specific molecular alterations in patients’ tumors.
Cleveland Clinic Expands Cancer Genomic Testing Capabilities
Cleveland Clinic now offers an advanced genomic testing platform as standard of care to patients with cancer. This expanded capability turns cancer treatment into a “stealth bullet” that allows clinicians to identify genetic defects and connect patients with individualized, lifesaving therapies.
NIH Awards $3.1M to Identify Novel Parkinson Disease Genes in Latinos
New funding will expand the LARGE-PD cohort study of Parkinson disease in Latinos to include a genome-wide association study and develop a Latino-specific polygenic risk score for PD.
Advancing Immunotherapy: A Conversation with Timothy Chan, MD, PhD
Timothy Chan, MD, PhD, the renowned cancer researcher who directs Cleveland Clinic’s new Center for Immunotherapy and Precision Immuno-Oncology, plans to use genomic analysis and high-throughput immunoprofiling to develop advanced targeted therapies.
Visualizing PTEN: Seeing Mutations Differently
Cleveland Clinic’s Genomic Medicine Institute is looking at the use of sophisticated 3-D modeling to help discern nuanced but important structural differences between germline PTEN variants associated with and predictive of a patient’s clinical condition.
The Clinical Utility of APOL1 Mutations in Treating Chronic Kidney Disease
A genetic mutation found only in individuals of African descent confers higher risk of chronic kidney disease. It could also be key in reducing transplant rejection.